Phase II study of Gleevec/imatinib mesylate (STI-571, NSC 716051) in neurofibromatosis (NF1) patients with plexiform neurofibromas

Trial Profile

Phase II study of Gleevec/imatinib mesylate (STI-571, NSC 716051) in neurofibromatosis (NF1) patients with plexiform neurofibromas

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Plexiform neurofibroma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top